1887

Abstract

The tegument protein pp65 of human cytomegalovirus (HCMV) is abundant in lytically infected human foreskin fibroblasts (HFF), as well as in virions and subviral dense bodies (DB). Despite this, we showed previously that pp65 is dispensable for growth in HFF. In the process of refining a DB-based vaccine candidate, different HCMV mutants were generated, expressing a dominant HLA-A2-presented peptide of the IE1 protein fused to pp65. One of the mutant viruses (RV-VM1) surprisingly showed marked impairment in virus release from HFF. We hypothesized that analysis of the phenotypic alterations of RV-VM1 would provide insight into the functions of pp65, poorly defined thus far. RV-VM1 infection resulted in nuclear retention of the fusion protein and reorganization of nuclear inclusion bodies. Coimmunoprecipitation experiments suggested that wild-type (wt) pp65 and pp65–VM1 were substrates of the viral pUL97 kinase and formed a complex with the viral RNA-export protein pUL69 and with pUL97 in lysates of infected cells. No evidence for an impairment of pUL97 within this complex was found. However, RV-VM1 replication in infected cells was resistant to a pUL97 inhibitor, and pUL97 inhibitors mimicked the mutant in terms of pp65 being retained in the nucleus. The results suggest that the life cycle of RV-VM1 was impeded at the stages of early-late transcription, RNA export or capsid maturation. wt-pp65 may play a role at these stages of infection, and complex formation with pUL69 and pUL97 may be important for that function.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.022293-0
2010-10-01
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/10/2531.html?itemId=/content/journal/jgv/10.1099/vir.0.022293-0&mimeType=html&fmt=ahah

References

  1. Azzeh, M., Honigman, A., Taraboulos, A., Rouvinski, A. & Wolf, D. G. ( 2006; ). Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology 354, 69–79.[CrossRef]
    [Google Scholar]
  2. Becke, S., Aue, S., Thomas, D., Schader, S., Podlech, J., Bopp, T., Sedmak, T., Wolfrum, U., Plachter, B. & Reyda, S. ( 2010; ). Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28, 6191–6198.[CrossRef]
    [Google Scholar]
  3. Beninga, J., Kropff, B. & Mach, M. ( 1995; ). Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 76, 153–160.[CrossRef]
    [Google Scholar]
  4. Besold, K., Frankenberg, N., Pepperl-Klindworth, S., Kuball, J., Theobald, M., Hahn, G. & Plachter, B. ( 2007; ). Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2–11-mediated immune evasion. J Gen Virol 88, 1429–1439.[CrossRef]
    [Google Scholar]
  5. Besold, K., Wills, M. & Plachter, B. ( 2009; ). Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. Virology 391, 5–19.[CrossRef]
    [Google Scholar]
  6. Borst, E. M., Hahn, G., Koszinowski, U. H. & Messerle, M. ( 1999; ). Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73, 8320–8329.
    [Google Scholar]
  7. Britt, W. J. & Auger, D. ( 1986; ). Human cytomegalovirus virion-associated protein with kinase activity. J Virol 59, 185–188.
    [Google Scholar]
  8. Chevillotte, M., Landwehr, S., Linta, L., Frascaroli, G., Luske, A., Buser, C., Mertens, T. & von Einem, J. ( 2009; ). Major tegument protein pp65 of human cytomegalovirus is required for the incorporation of pUL69 and pUL97 into the virus particle and for viral growth in macrophages. J Virol 83, 2480–2490.[CrossRef]
    [Google Scholar]
  9. Cui, Z., Zhang, K., Zhang, Z., Liu, Y., Zhou, Y., Wei, H. & Zhang, X. E. ( 2009; ). Visualization of the dynamic multimerization of human cytomegalovirus pp65 in punctuate nuclear foci. Virology 392, 169–177.[CrossRef]
    [Google Scholar]
  10. Dolan, A., Cunningham, C., Hector, R. D., Hassan-Walker, A. F., Lee, L., Addison, C., Dargan, D. J., McGeoch, D. J., Gatherer, D. & other authors ( 2004; ). Genetic content of wild-type human cytomegalovirus. J Gen Virol 85, 1301–1312.[CrossRef]
    [Google Scholar]
  11. Dunn, W., Chou, C., Li, H., Hai, R., Patterson, D., Stolc, V., Zhu, H. & Liu, F. ( 2003; ). Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A 100, 14223–14228.[CrossRef]
    [Google Scholar]
  12. Gallina, A., Simoncini, L., Garbelli, S., Percivalle, E., Pedrali-Noy, G., Lee, K. S., Erikson, R. L., Plachter, B., Gerna, G. & Milanesi, G. ( 1999; ). Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein. J Virol 73, 1468–1478.
    [Google Scholar]
  13. Gilloteaux, J. & Nassiri, M. R. ( 2000; ). Human bone marrow fibroblasts infected by cytomegalovirus: ultrastructural observations. J Submicrosc Cytol Pathol 32, 17–45.
    [Google Scholar]
  14. Grefte, J. M., van-der-Gun, B. T., Schmolke, S., van-der-Giessen, M., van-Son, W. J., Plachter, B., Jahn, G. & The, T. H. ( 1992a; ). Cytomegalovirus antigenemia assay: identification of the viral antigen as the lower matrix protein pp65. J Infect Dis 166, 683–684.[CrossRef]
    [Google Scholar]
  15. Grefte, J. M., van-der-Gun, B. T., Schmolke, S., van-der-Giessen, M., van-Son, W. J., Plachter, B., Jahn, G. & The, T. H. ( 1992b; ). The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 73, 2923–2932.[CrossRef]
    [Google Scholar]
  16. Griffiths, P. D., Emery, V. C. & Milne, R. ( 2009; ). Cytomegalovirus. In Clinical Virology, 3rd edn, pp. 475–506. Edited by Richman, D. D., Whitley, R. J. & Hayden, F. G.. Washington, DC. : American Society for Microbiology.
    [Google Scholar]
  17. Hamirally, S., Kamil, J. P., Ndassa-Colday, Y. M., Lin, A. J., Jahng, W. J., Baek, M. C., Noton, S., Silva, L. A., Simpson-Holley, M. & other authors ( 2009; ). Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 5, e1000275.[CrossRef]
    [Google Scholar]
  18. Herget, T., Freitag, M., Morbitzer, M., Kupfer, R., Stamminger, T. & Marschall, M. ( 2004; ). Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 48, 4154–4162.[CrossRef]
    [Google Scholar]
  19. Kalejta, R. F. ( 2008; ). Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 72, 249–265.[CrossRef]
    [Google Scholar]
  20. Kamil, J. P. & Coen, D. M. ( 2007; ). Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol 81, 10659–10668.[CrossRef]
    [Google Scholar]
  21. Krosky, P. M., Baek, M. C. & Coen, D. M. ( 2003; ). The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 77, 905–914.[CrossRef]
    [Google Scholar]
  22. Lischka, P., Rosorius, O., Trommer, E. & Stamminger, T. ( 2001; ). A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J 20, 7271–7283.[CrossRef]
    [Google Scholar]
  23. Lischka, P., Toth, Z., Thomas, M., Mueller, R. & Stamminger, T. ( 2006; ). The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. Mol Cell Biol 26, 1631–1643.[CrossRef]
    [Google Scholar]
  24. Maeda, F., Ihara, S. & Watanabe, Y. ( 1979; ). Morphogenesis of nuclear inclusions and virus capsids in HEL cells infected with temperature-sensitive mutants of human cytomegalovirus. J Gen Virol 44, 419–432.[CrossRef]
    [Google Scholar]
  25. Marschall, M., Helten, A., Hechtfischer, A., Zach, A., Banaschewski, C., Hell, W. & Meier-Ewert, H. ( 1999; ). The ORF, regulated synthesis, and persistence-specific variation of influenza C viral NS1 protein. Virology 253, 208–218.[CrossRef]
    [Google Scholar]
  26. Marschall, M., Stein-Gerlach, M., Freitag, M., Kupfer, R., van den Bogaard, M. & Stamminger, T. ( 2001; ). Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J Gen Virol 82, 1439–1450.
    [Google Scholar]
  27. Marschall, M., Stein-Gerlach, M., Freitag, M., Kupfer, R., van den Bogaard, M. & Stamminger, T. ( 2002; ). Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol 83, 1013–1023.
    [Google Scholar]
  28. Marschall, M., Freitag, M., Suchy, P., Romaker, D., Kupfer, R., Hanke, M. & Stamminger, T. ( 2003; ). The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311, 60–71.[CrossRef]
    [Google Scholar]
  29. Marschall, M., Marzi, A., aus dem Siepen, P., Jochmann, R., Kalmer, M., Auerochs, S., Lischka, P., Leis, M. & Stamminger, T. ( 2005; ). Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem 280, 33357–33367.[CrossRef]
    [Google Scholar]
  30. McLaughlin-Taylor, E., Pande, H., Forman, S. J., Tanamachi, B., Li, C. R., Zaia, J. A., Greenberg, P. D. & Riddell, S. R. ( 1994; ). Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43, 103–110.[CrossRef]
    [Google Scholar]
  31. Mersseman, V., Besold, K., Reddehase, M. J., Wolfrum, U., Strand, D., Plachter, B. & Reyda, S. ( 2008a; ). Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. J Gen Virol 89, 369–379.[CrossRef]
    [Google Scholar]
  32. Mersseman, V., Bohm, V., Holtappels, R., Deegen, P., Wolfrum, U., Plachter, B. & Reyda, S. ( 2008b; ). Refinement of strategies for the development of a human cytomegalovirus dense body vaccine. Med Microbiol Immunol (Berl) 197, 97–107.[CrossRef]
    [Google Scholar]
  33. Milbradt, J., Webel, R., Auerochs, S., Sticht, H. & Marschall, M. ( 2010; ). Novel mode of phosphorylation-triggered reorganization of the nuclear lamina during nuclear egress of human cytomegalovirus. J Biol Chem 285, 13979–13989.[CrossRef]
    [Google Scholar]
  34. Mocarski, E. S., Shenk, T. & Pass, R. F. ( 2007; ). Cytomegaloviruses. In Fields Virology, 5th edn, pp. 2701–2772. Edited by Knipe, D. M. & Howley, P. M.. Philadelphia, PA. : Lippincott Williams & Wilkins.
    [Google Scholar]
  35. Pande, H., Campo, K., Tanamachi, B. & Zaia, J. A. ( 1991; ). Human cytomegalovirus strain Towne pp65 gene: nucleotide sequence and expression in Escherichia coli. Virology 182, 220–228.[CrossRef]
    [Google Scholar]
  36. Plachter, B., Klages, S., Hagelmann, S., Britt, W., Landini, M. P. & Jahn, G. ( 1990; ). Procaryotic expression of phosphorylated tegument protein pp65 of human cytomegalovirus and application of recombinant peptides for immunoblot analyses. J Clin Microbiol 28, 1229–1235.
    [Google Scholar]
  37. Prichard, M. N., Britt, W. J., Daily, S. L., Hartline, C. B. & Kern, E. R. ( 2005; ). Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol 79, 15494–15502.[CrossRef]
    [Google Scholar]
  38. Prichard, M. N., Sztul, E., Daily, S. L., Perry, A. L., Frederick, S. L., Gill, R. B., Hartline, C. B., Streblow, D. N., Varnum, S. M. & other authors ( 2008; ). Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 82, 5054–5067.[CrossRef]
    [Google Scholar]
  39. Rechter, S., Scott, G. M., Eickhoff, J., Zielke, K., Auerochs, S., Muller, R., Stamminger, T., Rawlinson, W. D. & Marschall, M. ( 2009; ). Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J Biol Chem 284, 8605–8613.[CrossRef]
    [Google Scholar]
  40. Roby, C. & Gibson, W. ( 1986; ). Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J Virol 59, 714–727.
    [Google Scholar]
  41. Sanchez, V., Angeletti, P. C., Engler, J. A. & Britt, W. J. ( 1998; ). Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol 72, 3321–3329.
    [Google Scholar]
  42. Sanchez, V., Greis, K. D., Sztul, E. & Britt, W. J. ( 2000a; ). Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol 74, 975–986.[CrossRef]
    [Google Scholar]
  43. Sanchez, V., Sztul, E. & Britt, W. J. ( 2000b; ). Human cytomegalovirus pp28 (UL99) localizes to a cytoplasmic compartment which overlaps the endoplasmic reticulum–Golgi–intermediate compartment. J Virol 74, 3842–3851.[CrossRef]
    [Google Scholar]
  44. Schmolke, S., Drescher, P., Jahn, G. & Plachter, B. ( 1995a; ). Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 69, 1071–1078.
    [Google Scholar]
  45. Schmolke, S., Kern, H. F., Drescher, P., Jahn, G. & Plachter, B. ( 1995b; ). The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 69, 5959–5968.
    [Google Scholar]
  46. Somogyi, T., Michelson, S. & Masse, M. J. ( 1990; ). Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68). Virology 174, 276–285.[CrossRef]
    [Google Scholar]
  47. Thomas, M., Rechter, S., Milbradt, J., Auerochs, S., Muller, R., Stamminger, T. & Marschall, M. ( 2009; ). Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. J Gen Virol 90, 567–578.[CrossRef]
    [Google Scholar]
  48. Toth, Z. & Stamminger, T. ( 2008; ). The human cytomegalovirus regulatory protein UL69 and its effect on mRNA export. Front Biosci 13, 2939–2949.[CrossRef]
    [Google Scholar]
  49. Toth, Z., Lischka, P. & Stamminger, T. ( 2006; ). RNA-binding of the human cytomegalovirus transactivator protein UL69, mediated by arginine-rich motifs, is not required for nuclear export of unspliced RNA. Nucleic Acids Res 34, 1237–1249.[CrossRef]
    [Google Scholar]
  50. Warming, S., Costantino, N., Court, D. L., Jenkins, N. A. & Copeland, N. G. ( 2005; ). Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33, e36.[CrossRef]
    [Google Scholar]
  51. Wills, M. R., Carmichael, A. J., Mynard, K., Jin, X., Weekes, M. P., Plachter, B. & Sissons, J. G. ( 1996; ). The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70, 7569–7579.
    [Google Scholar]
  52. Winkler, M., Rice, S. A. & Stamminger, T. ( 1994; ). UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression. J Virol 68, 3943–3954.
    [Google Scholar]
  53. Wolf, D. G., Courcelle, C. T., Prichard, M. N. & Mocarski, E. S. ( 2001; ). Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci U S A 98, 1895–1900.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.022293-0
Loading
/content/journal/jgv/10.1099/vir.0.022293-0
Loading

Data & Media loading...

vol. , part 10, pp. 2531–2541

including:

[ Single PDF file] (80 KB)



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error